Free Trial

FibroGen (FGEN) News Today

FibroGen logo
$0.28 -0.01 (-4.86%)
Closing price 04:00 PM Eastern
Extended Trading
$0.29 +0.01 (+3.93%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
FibroGen's (FGEN) Market Perform Rating Reiterated at William Blair
William Blair Keeps Their Hold Rating on FibroGen (FGEN)
FibroGen Down on Peer-Review Publication
FibroGen options imply 18.1% move in share price post-earnings
FibroGen reports Q4 EPS 18c, consensus (20c)
FibroGen (FGEN) Gets a Hold from William Blair
FibroGen, Inc. stock logo
FibroGen (FGEN) Expected to Announce Quarterly Earnings on Monday
FibroGen (NASDAQ:FGEN) will be releasing earnings before the market opens on Monday, February 24.
FibroGen, Inc. stock logo
FibroGen (NASDAQ:FGEN) Receives Buy Rating from HC Wainwright
HC Wainwright reiterated a "buy" rating and issued a $10.00 target price on shares of FibroGen in a research note on Thursday.
FibroGen, Inc. stock logo
StockNews.com Initiates Coverage on FibroGen (NASDAQ:FGEN)
StockNews.com began coverage on shares of FibroGen in a research report on Friday. They issued a "hold" rating for the company.
FibroGen stock soars on China unit sale
FibroGen, Inc. stock logo
FibroGen, Inc. (NASDAQ:FGEN) Short Interest Down 5.2% in January
FibroGen, Inc. (NASDAQ:FGEN - Get Free Report) was the recipient of a significant drop in short interest during the month of January. As of January 31st, there was short interest totalling 2,910,000 shares, a drop of 5.2% from the January 15th total of 3,070,000 shares. Based on an average daily volume of 1,250,000 shares, the days-to-cover ratio is currently 2.3 days.
FibroGen, Inc. stock logo
FibroGen (NASDAQ:FGEN) Shares Pass Above 50 Day Moving Average - Here's What Happened
FibroGen (NASDAQ:FGEN) Stock Price Passes Above Fifty Day Moving Average - What's Next?
Perspective Therapeutics appoints Graham as CFO
FibroGen, Inc. stock logo
FibroGen (NASDAQ:FGEN) Coverage Initiated by Analysts at StockNews.com
StockNews.com began coverage on FibroGen in a research note on Wednesday. They set a "hold" rating for the company.
FibroGen initiated with a Buy at H.C. Wainwright
FibroGen Appoints David DeLucia as Chief Financial Officer
FibroGen (NASDAQ:FGEN) Stock, Option Chain
FibroGen Reports Strong Q3 Growth and Future Plans
FibroGen Reports Third Quarter 2024 Financial Results
FibroGen to Report Third Quarter 2024 Financial Results
Disc Medicine appoints Kaushik as Chief Technical Officer
FibroGen to exit Mission Bay lease early
FibroGen announces executive departures amid cost cuts
FGEN Sep 2024 2.500 call
Remove Ads
Get FibroGen News Delivered to You Automatically

Sign up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter.

FGEN Media Mentions By Week

FGEN Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

FGEN
News Sentiment

0.30

0.61

Average
Medical
News Sentiment

FGEN News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

FGEN Articles
This Week

8

1

FGEN Articles
Average Week

Remove Ads
Get FibroGen News Delivered to You Automatically

Sign up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:FGEN) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners